Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status.

导出 LinkOut

翻译打印收藏纠错

第一作者： Ali,Calderon-Aparicio

第一单位： These authors contributed equally to this work.

作者： Ali,Calderon-Aparicio ^[1] ; Alejandro,Cornejo ^[1] ; Andrea,Orue ^[2] ; Manuel,Rieber ^[2]

作者单位： These authors contributed equally to this work. ^[1] Instituto Venezolano de Investigaciones Cientificas, Tumor Cell Biology Laboratory, Caracas 1020-A, Venezuela.;These authors contributed equally to this work. ^[2]

关键词 Cu chelation Cu-MEK activation KRAS/c-MYC disulfiram oxaliplatin p53 status tetrathiomolybdate

DOI 10.3332/ecancer.2019.890

PMID 30792807

发布时间 2022-03-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Ecancermedicalscience

2019年13卷

890页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status.

Ecancermedicalscience

相似文献

Ecancermedicalscience

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status.

Ecancermedicalscience

相似文献

Ecancermedicalscience

相关期刊

检索历史清除